Disease · MONDO_0015183
Comparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 28
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NT,PBO/TED vs TED/TED: serious adverse events | 32 of 51 | 24 of 37 | 88 | NCT00930644 | Trial comparisons |
| Teduglutide vs Placebo: serious adverse events | 15 of 42 | 12 of 43 | 85 | NCT00798967 | Trial comparisons |
| Low Dose ECC Regimen vs High Dose ECC Regimen: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT04046328 | Trial comparisons |
| Low Dose ECC Regimen vs High Dose ECC Regimen: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT04046328 | Trial comparisons |
| Teduglutide vs Placebo: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT02099084 | Trial comparisons |
| SHP633-306: Teduglutide 0.05 mg/kg vs TED-C14-004: Teduglutide 0.05 mg/kg: Number of Participants Who Were Completely Weaned Off PS at End of Study (EOS) | 1 of 4 | 2 of 7 | 11 | NCT03596164 | Trial comparisons |
SHP633-306: Teduglutide 0.05 mg/kg vs TED-C14-004: Teduglutide 0.05 mg/kg: Number of Participants Who Demonstrated at Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume | 3 of 4 | 5 of 7 | 11 | NCT03596164 | Trial comparisons |
Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants With Clinically Significant Changes in Vital Signs Reported as Treatment Emergent Adverse Events (TEAEs) | 0 of 8 | 0 of 2 | 10 | NCT02980666 | Trial comparisons |
Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Treatment Emergent Adverse Events (TEAEs) | 0 of 8 | 0 of 2 | 10 | NCT02980666 | Trial comparisons |
| Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 8 of 8 | 2 of 2 | 10 | NCT02980666 | Trial comparisons |
Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants Who Achieved Greater Than or Equal to (>=) 20 Percent (%) Reduction in Parenteral Support (PS) Volume at Week 28 | 3 of 8 | 1 of 2 | 10 | NCT02980666 | Trial comparisons |
Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning of Parenteral Support (PS) Volume at End of Treatment (EOT) | 1 of 8 | 0 of 2 | 10 | NCT02980666 | Trial comparisons |
Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants Who Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at End of Treatment (EOT) | 4 of 8 | 1 of 2 | 10 | NCT02980666 | Trial comparisons |
| Total Children (Aged: 1 - 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): deaths from any cause | 0 of 8 | 0 of 2 | 10 | NCT02980666 | Trial comparisons |
| Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants With Positive Specific Antibodies to Teduglutide | 1 of 8 | 2 of 2 | 10 | NCT02980666 | Trial comparisons |
Total Children (Aged: 1 to 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Treatment Emergent Adverse Events (TEAEs) | 0 of 8 | 0 of 2 | 10 | NCT02980666 | Trial comparisons |
| Total Children (Aged: 1 - 15 Years) vs Infants (Corrected Gestational Age: 4 to < 12 Months): serious adverse events | 6 of 8 | 2 of 2 | 10 | NCT02980666 | Trial comparisons |
| Teduglutide (TED) vs Standard of Care (SOC): Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 5 of 5 | 5 of 5 | 10 | NCT03571516 | Trial comparisons |
| Teduglutide (TED) vs Standard of Care (SOC): deaths from any cause | 0 of 5 | 0 of 5 | 10 | NCT03571516 | Trial comparisons |
| Teduglutide (TED) vs Standard of Care (SOC): serious adverse events | 4 of 5 | 3 of 5 | 10 | NCT03571516 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015183/comparisons